JP2024517807A - ヌクレオチド及びヌクレオシド治療組成物、組合せ、並びにそれらに関連する使用 - Google Patents
ヌクレオチド及びヌクレオシド治療組成物、組合せ、並びにそれらに関連する使用 Download PDFInfo
- Publication number
- JP2024517807A JP2024517807A JP2023567884A JP2023567884A JP2024517807A JP 2024517807 A JP2024517807 A JP 2024517807A JP 2023567884 A JP2023567884 A JP 2023567884A JP 2023567884 A JP2023567884 A JP 2023567884A JP 2024517807 A JP2024517807 A JP 2024517807A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- amino
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184609P | 2021-05-05 | 2021-05-05 | |
| US63/184,609 | 2021-05-05 | ||
| PCT/US2022/027784 WO2022235874A1 (en) | 2021-05-05 | 2022-05-05 | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517807A true JP2024517807A (ja) | 2024-04-23 |
| JP2024517807A5 JP2024517807A5 (cg-RX-API-DMAC7.html) | 2025-05-14 |
Family
ID=83932924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567884A Pending JP2024517807A (ja) | 2021-05-05 | 2022-05-05 | ヌクレオチド及びヌクレオシド治療組成物、組合せ、並びにそれらに関連する使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250281519A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4333859A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517807A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117881402A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216679A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022235874A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| CN116199730A (zh) * | 2023-04-24 | 2023-06-02 | 南京颐媛生物医学研究院有限公司 | 4-硫代尿嘧啶核糖核苷磷酸酯化合物及其制备方法和应用 |
| CN117567310A (zh) * | 2023-11-28 | 2024-02-20 | 重庆智合生物医药有限公司 | 一种神经酰胺np1的合成方法 |
| WO2026043895A1 (en) * | 2024-08-19 | 2026-02-26 | Altesa BioSciences, Inc. | Method of treating respiratory conditions in chronic obstructive pulmonary disease patients |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517848A (ja) * | 2000-12-18 | 2004-06-17 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 抗ウイルス剤 |
| JP2011520991A (ja) * | 2008-05-27 | 2011-07-21 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 抗ウイルス剤の塩 |
| WO2011160191A1 (en) * | 2010-06-25 | 2011-12-29 | Biota Scientific Management Pty Ltd | Compound for the treatment of enteroviruses |
| WO2016145142A1 (en) * | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201542581A (zh) * | 2013-09-11 | 2015-11-16 | 艾默理大學 | 核苷酸與核苷治療組成物及其相關用途 |
| KR20260028884A (ko) * | 2018-03-07 | 2026-03-04 | 에모리 유니버시티 | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 |
-
2022
- 2022-05-05 CA CA3216679A patent/CA3216679A1/en active Pending
- 2022-05-05 WO PCT/US2022/027784 patent/WO2022235874A1/en not_active Ceased
- 2022-05-05 CN CN202280043048.3A patent/CN117881402A/zh active Pending
- 2022-05-05 JP JP2023567884A patent/JP2024517807A/ja active Pending
- 2022-05-05 US US18/558,874 patent/US20250281519A1/en active Pending
- 2022-05-05 EP EP22799556.0A patent/EP4333859A4/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517848A (ja) * | 2000-12-18 | 2004-06-17 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 抗ウイルス剤 |
| JP2011520991A (ja) * | 2008-05-27 | 2011-07-21 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 抗ウイルス剤の塩 |
| WO2011160191A1 (en) * | 2010-06-25 | 2011-12-29 | Biota Scientific Management Pty Ltd | Compound for the treatment of enteroviruses |
| WO2016145142A1 (en) * | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4333859A4 (en) | 2025-03-26 |
| CA3216679A1 (en) | 2022-11-10 |
| WO2022235874A1 (en) | 2022-11-10 |
| US20250281519A1 (en) | 2025-09-11 |
| EP4333859A1 (en) | 2024-03-13 |
| CN117881402A (zh) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7508501B2 (ja) | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 | |
| JP7786743B2 (ja) | 4’-ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| WO2016145142A1 (en) | Nucleotide and nucleoside therapeutics compositions and uses related thereto | |
| US20250281519A1 (en) | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto | |
| JP7129703B2 (ja) | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 | |
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| WO2017155923A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| HK40075390A (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| EA040007B1 (ru) | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения | |
| HK40005242A (zh) | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 | |
| EA047160B1 (ru) | Терапевтические композиции 4'-галогенсодержащих нуклеотидов и нуклеозидов и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260616 |